Compare · IDXX vs ORKA
IDXX vs ORKA
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $53.28B, about 8.2x ORKA ($6.50B).
- Over the past year, IDXX is down 6.8% and ORKA is up 228.3% - ORKA leads by 235.2 points.
- ORKA has been more active in the news (13 items in the past 4 weeks vs 11 for IDXX).
- IDXX has more recent analyst coverage (25 ratings vs 11 for ORKA).
- Company
- IDEXX Laboratories Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $53.28B
- $6.50B
- 1M return
- +19.31%
- +18.08%
- 1Y return
- -6.85%
- +228.31%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- News (4w)
- 11
- 13
- Recent ratings
- 25
- 11
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest IDXX
- Executive Vice President Michael Lane exercised 863 shares at a strike of $346.59, increasing direct ownership by 21% to 4,939 units (SEC Form 4)
- Executive Chair of the Board Jonathan Jay Mazelsky gifted 700 shares, decreasing direct ownership by 0.84% to 83,103 units (SEC Form 4)
- Executive Vice President Fennell George exercised 1,749 shares at a strike of $171.38, increasing direct ownership by 17% to 12,182 units (SEC Form 4)
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 8,906 shares at a strike of $288.78 and sold $6,132,605 worth of shares (8,906 units at $688.59) (SEC Form 4)
- Executive Vice President Lane Michael sold $2,740,069 worth of shares (3,979 units at $688.64), decreasing direct ownership by 49% to 4,076 units (SEC Form 4)
- Executive Chair of the Board Mazelsky Jonathan Jay exercised 25,140 shares at a strike of $178.26 and sold $17,678,195 worth of shares (25,140 units at $703.19) (SEC Form 4)
- Director Junius Daniel M sold $844,888 worth of shares (1,200 units at $704.07), decreasing direct ownership by 34% to 2,361 units (SEC Form 4)
- Director Hooley Joseph L was granted 48 shares, increasing direct ownership by 15% to 373 units (SEC Form 4)
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest ORKA
- General Counsel Paul T Quinlan exercised 9,000 shares at a strike of $7.80 and sold $853,986 worth of shares (9,000 units at $94.89) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $706,700 worth of shares (7,000 units at $100.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Oruka Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,049,658 worth of shares (10,000 units at $104.97) as part of a pre-agreed trading plan (SEC Form 4)
- Director Ball Kristine M exercised 18,000 shares at a strike of $6.84 and sold $1,888,749 worth of shares (18,000 units at $104.93) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,390,125 worth of shares (25,000 units at $95.60) as part of a pre-agreed trading plan (SEC Form 4)